Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3432014 | 0.83 | TGFBR1 (0.38) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL27533966 | 0.79 | ALDH1A1 (0.33) | ALDH1A1TGFBR1 | |
| SCHEMBL3430617 | 0.78 | ALDH1A1 (0.36) | ALDH1A1CA1CA2MGAMGAA | |
| SCHEMBL446082 | 0.77 | ALDH1A1 (0.34) | ALDH1A1CA1CA2MGAMGAA | |
| Ammonia Solution, Strong SCHEMBL27426631 | 0.77 | ALDH1A1 (0.34) | ALDH1A1CA1CA2MGAMGAA | |
| SCHEMBL1786823 | 0.77 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL1786824 | 0.77 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL8011252 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL28202294 | 0.76 | ALDH1A1 (0.31) | ALDH1A1TGFBR1 | |
| SCHEMBL27691668 | 0.75 | GPR84 (0.32) | ALDH1A1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | ALDH1A1 1706/4885TSHR 4451/4885CA1 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.